PL2262493T3 - Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu - Google Patents

Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu

Info

Publication number
PL2262493T3
PL2262493T3 PL09717048T PL09717048T PL2262493T3 PL 2262493 T3 PL2262493 T3 PL 2262493T3 PL 09717048 T PL09717048 T PL 09717048T PL 09717048 T PL09717048 T PL 09717048T PL 2262493 T3 PL2262493 T3 PL 2262493T3
Authority
PL
Poland
Prior art keywords
belinostat
methods
continuous infusion
treatment employing
prolonged continuous
Prior art date
Application number
PL09717048T
Other languages
English (en)
Polish (pl)
Inventor
Maxwell Sehested
Peter Buhl Jensen
Nis Nissen
Original Assignee
Onxeo Dk Branch Of Onxeo S A France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo Dk Branch Of Onxeo S A France filed Critical Onxeo Dk Branch Of Onxeo S A France
Publication of PL2262493T3 publication Critical patent/PL2262493T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL09717048T 2008-03-07 2009-03-06 Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu PL2262493T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat
EP09717048.4A EP2262493B1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (1)

Publication Number Publication Date
PL2262493T3 true PL2262493T3 (pl) 2015-08-31

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09717048T PL2262493T3 (pl) 2008-03-07 2009-03-06 Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu

Country Status (14)

Country Link
US (1) US20110003777A1 (enExample)
EP (1) EP2262493B1 (enExample)
JP (1) JP5615189B2 (enExample)
CN (1) CN102083428A (enExample)
AU (1) AU2009220942B2 (enExample)
CA (1) CA2717207A1 (enExample)
DK (1) DK2262493T3 (enExample)
EA (1) EA022880B1 (enExample)
ES (1) ES2536208T3 (enExample)
MX (1) MX2010009642A (enExample)
PL (1) PL2262493T3 (enExample)
PT (1) PT2262493E (enExample)
SI (1) SI2262493T1 (enExample)
WO (1) WO2009109861A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
JP6159567B2 (ja) * 2012-04-27 2017-07-05 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 既製のゲムシタビン注入溶液
CN103839548B (zh) 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
IL142531A0 (en) * 1998-10-13 2002-03-10 Fujisawa Pharmaceutical Co Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
DK1233958T3 (da) * 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
EP1431267A4 (en) * 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
DE60318387T2 (de) * 2002-01-11 2008-12-18 Rath, Matthias, Dr. Polyphenole enthaltende pharmazeutische nahrungsmittelergänzungsformel und ihre anwendung in der krebsbehandlung
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7495022B2 (en) * 2002-04-11 2009-02-24 Sk Chemicals Co., Ltd. α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
PL379887A1 (pl) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
JP2007511212A (ja) * 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
ATE437370T1 (de) * 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
DE602004014723D1 (de) * 2004-04-30 2008-08-14 Desitin Arzneimittel Gmbh Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung
JPWO2006014024A1 (ja) * 2004-08-06 2008-05-01 小野薬品工業株式会社 精神神経系疾患治療剤
KR20070057822A (ko) * 2004-08-09 2007-06-07 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
CA2594477C (en) * 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
ES2380887T3 (es) * 2005-05-13 2012-05-21 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
EP2361619A1 (en) * 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
BRPI0710073A2 (pt) * 2006-02-22 2011-08-02 4Sc Ag indolopiridinas
US8530493B2 (en) * 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
MX2010009642A (es) 2010-09-22
WO2009109861A1 (en) 2009-09-11
DK2262493T3 (en) 2015-04-27
EA022880B1 (ru) 2016-03-31
PT2262493E (pt) 2015-06-02
US20110003777A1 (en) 2011-01-06
EP2262493B1 (en) 2015-02-25
CN102083428A (zh) 2011-06-01
ES2536208T3 (es) 2015-05-21
AU2009220942A1 (en) 2009-09-11
JP2011513378A (ja) 2011-04-28
HK1152247A1 (en) 2012-02-24
EA201070913A1 (ru) 2011-04-29
CA2717207A1 (en) 2009-09-11
EP2262493A1 (en) 2010-12-22
AU2009220942A8 (en) 2012-08-30
AU2009220942B2 (en) 2015-05-28
SI2262493T1 (sl) 2015-07-31
JP5615189B2 (ja) 2014-10-29

Similar Documents

Publication Publication Date Title
ZA201006648B (en) Methods of treatment
NO2016023I1 (no) Glycerol fenylbutyrat
GB0802116D0 (en) Treatment
HUE056843T2 (hu) Gyógyszerek infúziója
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
GB0811992D0 (en) Treatment
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
EP2164494A4 (en) Methods of Treatment
SI2262493T1 (sl) Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP2303284A4 (en) METHOD FOR TREATING BIPOLAR DISORDER
GB0723100D0 (en) Treatment of HFnEF
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB0814043D0 (en) The treatment of skin disorders
GB2465211B (en) Treatment Solution
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak
GB0700969D0 (en) Methods of treatment
GB0809319D0 (en) The treatment of puritus
GB0801410D0 (en) Therapeutic intervention
GB0817740D0 (en) New therapeutic use
GB0817737D0 (en) New therapeutic use
GB0817738D0 (en) New therapeutic use
GB0816979D0 (en) New therapeutic use
GB0817739D0 (en) New therapeutic use